IVG-PREMIUM-E-LIQUIDS
25.3.2019 10:04:10 CET | Business Wire | Press release
IVG Premium E-Liquids, the UK’s market-leading brand, has announced a strategic partnership with globally renowned Kollaras & Co – A 3rd generation, family owned and operated business. Kollaras & Co specialises in supporting independent retailers across multiple channels in Australia.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190325005029/en/
Kollaras & Co have landed the master distribution rights for IVG products within Australia, which will allow vapers from down under to join vapers from over 60 countries and 6 continents that vape premium British flavours from IVG.
John Kollaras, Managing Director of Kollaras & Co, commented that the alliance was an important step for the near 60-year-old business, commenting “We are thrilled to partner with IVG, as we continue to strive to provide a unique offering within our portfolio, and cement our position as a dynamic solutions provider.” Kollaras continued: “Quality, authenticity and passion are three key values which we look for in partners, and IVG is no exception to this.”
Ahsan Bawa, CEO of IVG, commented that “Our incredible journey continues here at IVG, our multi international and award winning brand continues to reach new heights. We are proud and honoured to welcome the Kollaras family into our own, and this strategic alliance will help in those efforts on delivering IVG to a store near you. We are thrilled to officially announce the partnership with Kolloras & Co, a key step for Oceania & South Pacific regions
Kollaras & Co will be distributing 26 delicious e-liquid flavours in 60 ML and 10 ML from IVG Premium E-Liquids’ into the Australia retail market sector by the end of April 2019.
13 International Accolades “Leading E-Liquids Specialist 2019”, Best Sweet Flavour, and more have played a key role in the Australia company taking the products on board, along with the existing reviews of the vape enthusiasts in the Australian market.
Kollaras closed by adding “Our core innovation metrics focus on creating brands that are valued by our customers and deliver outstanding value to their shoppers, and IVG is a fantastic example of this. We are both confident and excited about the partnership and our growth prospects in the year ahead to say the least!”
About IVG Premium E-Liquids - www.ivgeliquids.co.uk
About Kollaras & Co: www.kollaras.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20190325005029/en/
Contact:
Media Contact: Deepika Patel Head of Marketing +44 (0) 1772 217000 deepika.patel@ivgeliquids.com
Social Media:
https://www.facebook.com/ivgeliquids
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
First Plus Expands Relationship with SS&C to Support Cross-Border Operations in APAC3.8.2026 03:00:00 CEST | Press release
SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced that First Plus Asset Management (FPAM), a multi-asset investment management firm, has selected SS&C to provide cross-border operations support across Asia. SS&C will service First Plus across the full investment lifecycle, delivering a scalable, integrated solution supporting transfer agency, order management and execution and investment accounting. FPAM will utilize SS&C to service its growing cross-border operating model and support around $200 million in assets under management*. “As First Plus has expanded, managing our operations has become increasingly complex,” said Jeb Li, Co-Founder and CEO at First Plus. “SS&C’s global footprint and integrated offerings enable us to easily optimize our workflows, so we can focus on scaling quickly and securely while continuing to deliver risk-adjusted returns and best-in-class client service.” The engagement highlights the breadth and scalability of SS&C’s global service model.
Europe’s Largest Celebration of Irish Culture Arrives in Belfast2.8.2026 10:01:00 CEST | Press release
Fleadh Cheoil na hÉireann arrives in Belfast today (2 August), bringing eight days of traditional music, culture and celebration to the city, with organisers expecting up to 800,000 visitors over the course of the festival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260729147569/en/ Belfast Fleadh - Maddens Bar accordian, guitar and fiddle player (Chris Heaney) One of Europe’s largest cultural events, Fleadh Cheoil na hÉireann is taking place in Belfast for the first time, transforming the city into a vibrant stage for Irish music, dance, language and culture. More than 200 events and 180 traditional music competitions are taking place across venues, streets and neighbourhoods throughout the week-long celebration. The landmark festival showcases the very best of Irish culture, with a packed programme of All-Ireland competitions, concerts, community events and performances from both established and emerging artists. As Ir
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom